ArticleCureus2025
Unexpectedly Low HbA1c in a Patient With Newly Diagnosed Diabetes Mellitus and Thalassemia Trait: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemoglobin A1c (HbA1c) is widely used to assess long-term glycemic control in patients with diabetes mellitus; however, its reliability may be compromised in certain clinical scenarios, including hemoglobinopathies. We report the case of a 46-year-old man who presented with symptoms of hyperglycemia and was found to have diabetic ketosis. Despite significant hyperglycemia, his HbA1c was markedly low. Further evaluation confirmed the presence of thalassemia trait, which explained the discrepancy due to its impact on red blood cell turnover and HbA1c assay interference. This case highlights the importance of recognizing conditions that can distort HbA1c values and the need to use alternative glycemic monitoring strategies such as continuous glucose monitoring, corrected HbA1c, and serum fructosamine in such patients. Accurate interpretation of glycemic markers in the context of hemoglobinopathies is essential for appropriate diagnosis and effective diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.